These new drugs have made the most money since their market debut last year. [© Saharrr - Fotolia.com]
#10. Linzess™ (linaclotide)
2012 sales: $19.2 million9
Marketer(s): Ironwood Pharmaceuticals and Forest Laboratories
Indication(s): Irritable bowel syndrome with constipation and chronic idiopathic constipation in adults
Date of FDA approval: August 30, 2012
#9. Erivedge® (vismodegib)
2012 sales: $30.9 million (CHF 29 million)10
Marketer(s): Roche (Genentech)
Indication(s): Advanced basal cell carcinoma in adults who cannot have surgery or radiation therapy
Date of FDA approval: January 30, 2012
#8. Zaltrap® (ziv-aflibercept)
2012 sales: $32.3 million (€25 million)11
Marketer(s): Sanofi and Regeneron
Indication(s): Metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI) chemotherapy regimen
Date of FDA approval: August 3, 2012
Date of European Commission approval: February 5, 2013
#7. Stivarga™ (regorafenib)
2012 sales: $41.4 million (€32 million)12,13
Marketer(s): Bayer HealthCare and Onyx Pharmaceuticals
Indication(s): Metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy
Date of FDA approval: September 27, 2012
#6. Stribild™ (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)
2012 sales: $57.536 million14
Marketer(s): Gilead Sciences
Indication(s): HIV-1 infection in adults who are antiretroviral treatment-naïve
Date of FDA approval: August 27, 2012
#5. Perjeta® (pertuzumab)
2012 sales: $59.7 million (CHF 56 million)15
Marketer(s): Roche (Genentech)
Indication(s): First-line treatment of HER2-positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, in combination with Herceptin® (trastuzumab) and docetaxel
Date of FDA approval: June 8, 2012
Date of European Commission approval: March 5, 2013
#4. Kyprolis® (carfilzomib)
2012 sales: $64 million
Marketer(s): Onyx Pharmaceuticals
Indication(s): Multiple myeloma in patients who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy
Date of FDA approval: July 20, 2012
#3. Inlyta® (axitinib)
2012 sales: $70.1 million16
Marketer(s): Pfizer
Indication(s): Advanced renal cell carcinoma after failure of one prior systemic therapy
Date of FDA approval: January 27, 2012
Date of European Commission approval: September 4, 2012
#2. Xtandi® (enzalutamide)
2012 sales: $71.5 million
Marketer(s): Medivation and Astellas Pharma
Indication(s): Metastatic, castration-resistant prostate cancer in men who have previously received treatment with docetaxel
Date of FDA approval: August 31, 2012
#1. Kalydeco™ (ivacaftor)
2012 sales: $171.6 million
Marketer(s): Vertex Pharmaceuticals
Indication(s): Cystic fibrosis (CF) in patients 6 years old and older who have at least one copy of the G551D mutation in the CF transmembrane conductance regulator (CFTR) gene
Date of FDA approval: January 31, 2012
Date of European Commission approval: July 23, 2012
Notes:
1 No sales figure announced by company; figure reported by Zacks Investment Research, though Xeljanz sales were reported at $18 million by EvaluatePharma.
2 No sales figure announced by company; worldwide sales figure reported by EvaluatePharma.
3 No sales figure announced by company; worldwide sales figure reported by EvaluatePharma.
4 Sales figure converted to USD via XE (www.xe.com) on April 4, 2013.
5 No sales figure announced by company; worldwide sales figure reported by EvaluatePharma.
6 Figure reflects value of initial trade stocking of the product as disclosed by Forest Laboratories in its January 15 announcement of fiscal year 2013 third-quarter results: http://investor.frx.com/press-release/corporate-news/forest-laboratories-inc-reports-fiscal-year-2013-third-quarter-earnings
7 No sales figure announced by company; figure reported by Zacks Investment Research; EvaluatePharma reported $7 million in Bosulif sales for 2012.
8 No sales figure announced by either company; worldwide sales figure reported by EvaluatePharma.
9 Figure reflects value of initial trade stocking of the product as disclosed by Forest Laboratories in its January 15 announcement of fiscal year 2013 third-quarter results: http://investor.frx.com/press-release/corporate-news/forest-laboratories-inc-reports-fiscal-year-2013-third-quarter-earnings
10 Sales figure converted to USD via XE (www.xe.com) on April 4, 2013.
11 Sales figure converted to USD via XE (www.xe.com) on April 4, 2013.
12 Sales figure converted to USD via XE (www.xe.com) on April 4, 2013.
13 Figure does not include Onyx’s 20% royalty received on Bayer’s global net sales of Stivarga in human oncology. For full-year 2012, Onyx reported receiving $8.3 million in royalty revenue.
14 Sales for 2012 furnished to thousandths by Gilead Sciences.
15 Sales figure converted to USD via XE (www.xe.com) on April 4, 2013.
16 No sales figure announced by company; figure reported by Zacks Investment Research, citing its Zacks Model; EvaluatePharma reported a 2012 sales figure for Inlyta of $70 million.